---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-24-000081"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2024-10-16T23:59:59+00:00"
generated_at: "2026-05-30T13:48:26.339008+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics appoints Yung H. Chyung as Chief Medical Officer

## Summary
- Dr. Chyung appointed Chief Medical Officer effective November 1, 2024, succeeding Simon Cooper.
- He will receive an annual base salary of $510,000 and a target bonus of 40% of base salary.
- Eligible for a stock option to purchase 110,000 shares vesting over four years.
- Previously Executive VP and CMO at Tourmaline Bio (2022-2024) and CMO at Scholar Rock (2016-2022).
- Company press release issued October 16, 2024, announcing the appointment.

## SEC filing metadata
- accession: 0001664710-24-000081
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2024-10-16T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000081/0001664710-24-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000081/kros-20241015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-24-000081
- JSON: https://secwatch.observer/filing/0001664710-24-000081.json
- Plain text: https://secwatch.observer/filing/0001664710-24-000081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.